Positive Data from Nanoscope's Phase 1/2a Trial of Gene Therapy to Restore Vision in Patients Blinded by Retinitis Pigmentosa to be Featured at 2021 American Society of Retina Specialists Meeting

Two presentations will highlight positive data from the 52-week follow-up of patients who received a single intravitreal injection of Multi-Characteristic Opsin Gene Therapy

News provided by

Nanoscope Therapeutics

Oct 08, 2021, 07:00 ET

BEDFORD, Texas, Oct. 8, 2021 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, today announced findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) will be highlighted in two presentations during the 2021 Annual Meeting of the American Society of Retina Specialists (ASRS) October 8 – 12 at JWMarriott San Antonio, TX.

The presentations will be made by Dr. Sai Chavala, MD, a professor at TCU-UNTHSC Medical School. Dr. Chavala's presentation titled, "Intravitreal AAV2 Optogenetic Vision Restoration in Retinal Degenerative Patients with ABCA4 Mutation," will be on Sunday, October 10, 2:46 pm -2:50 pm, during an In the Pipeline session exploring new therapies.

Dr. Chavala will detail findings from four RP patients with ABCA4 mutation from the Phase1/2a trial who showed overall improvement in vision after 52 weeks of receiving a single intravitreal injection of MCO-010.

Dr. Chavala will discuss data from all 11 RP patients in the Phase1/2a trial in a Video on Demand, titled "Safety and Efficacy of Intravitreal Optogenetic Gene Therapy for Advanced Retinitis Pigmentosa," as part of the ASRS Virtual Annual Meeting Program. Results showed the therapy was well-tolerated and all patients experienced improvement in vision following MCO-010 injection.

MCO-010 uses a proprietary AAV2 vector to deliver MCO genes into retinal cells where they express polychromatic opsins sensitive to ambient light for vision restoration in different color environments. The therapy focuses on disease phenotype, enabling treatment of retinal degenerative diseases regardless of genetic mutations.

Results of a randomized, double-masked Phase 2b multi-center trial (NCT04945772) of MCO-010s are expected in Q4 2022. MCO-010 has orphan drug designations from the FDA for RP and Stargardt disease, which are known to be associated with ABCA4 mutation.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company's pipeline includes optogenetics-based retinal gene therapies for patients with RP, Stargardt disease, and dry age-related macular degeneration.

Contact:
Dan Eramian
Opus Biotech Communications
[email protected]
425-306-8716

SOURCE Nanoscope Therapeutics